Ischemic cardiomyopathy undergoing coronary artery bypass surgery
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
6
ADR-002K administration
Osaka University Hospital
Suita, Osaka, Japan
RECRUITINGNumber of participants with Adverse event
Safety assessment related to adverse events and this product
Time frame: 26 weeks
Amount of change in late gadolinium contrast-enhanced area at the time of screening and 6 months after surgery
Efficacy (Exploratory)
Time frame: 26 weeks
Number of complication associated with drug administration method
Feasibility of drug administration method
Time frame: 26 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.